March 4, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Subject: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Tetracycline Hydrochloride Capsules”

Thanking you,

Yours faithfully,

For Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary

Encl. As above
Strides receives USFDA approval for Tetracycline Hydrochloride Capsules

Product approval from flagship facility in Bangalore
To be marketed by Strides Pharma Inc. in the US market

Bangalore, March 04, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Tetracycline Hydrochloride Capsules USP, 250 mg and 500 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Achromycin V Capsules, 250 mg and 500 mg, of Avet Pharmaceuticals Inc (previously Heritage Pharmaceuticals Inc.)

According to IQVIA MAT data, the US market for Tetracycline Hydrochloride Capsules USP, 250 mg and 500 mg is approximately US$ 16 Mn. The product will be manufactured at the company’s flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 123 cumulative ANDA filings with USFDA of which 84 ANDAs have been approved and 39 are pending approval.

About Tetracycline Hydrochloride Capsules

Tetracycline Hydrochloride Capsule is an antibiotic used to treat many different bacterial infections of the skin, intestines, respiratory tract, urinary tract, genitals, lymph nodes, and other body systems. In some cases, tetracycline Hydrochloride Capsule is used when penicillin or another antibiotic cannot be used to treat serious infections such as Anthrax, Listeria, Clostridium, Actinomyces.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com
For further information, please contact:

**Strides**
Badree Komandur  
Executive Director - Finance  
+91 80 6784 0747

**Investor Relations:**  
Kannan. N: +91 98450 54745  
Vikesh Kumar: +91 80 6784 0827  
Sandeep Baid: +91 80 6784 0791  
Email: Sandeep.baid@strides.com

**Strides Pharma Science Limited**  
(Formerly Strides Shasun Limited)  
CIN: L24230MH1990PLC057062

Regd. Office: 201, ‘Devavrata’, Sector - 17,  
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta  
Road, Bangalore – 560 076

**PR Consultancy**  
Fortuna PR  
K Srinivas Reddy: +91 90005 27213  
srinivas@fortunapr.com

K Priya: +91 95354 25418  
priya@fortunapr.com